Thermo Fisher Scientific [NYSE:TMO]
Pioneering The Path From Laboratory To Life-Saving Treatment

Turning a promising pharmaceutical concept into reality is a massive challenge, one that demands constant innovation and a radical overhaul of the traditional drug development process. At the core of this complex journey are contract development and manufacturing organizations (CDMOs), vital players whose expertise is transforming the healthcare industry.

Imagine embarking on this ambitious project with a partner by your side from day one. This collaboration would span from the initial spark of creativity in the laboratory to the momentous delivery of a new treatment to patients. Such a partnership goes beyond merely accelerating the process; it represents a shared vision and commitment to pioneering a new drug development and manufacturing era.

Thermo Fisher Scientific’s Pharma Services exemplifies this approach in the CDMO field. It bridges the gap from concept to cure by rewriting the drug development and marketing playbook. Thermo Fisher's strategy isn’t just about modifying existing methods but setting new benchmarks and shaping the future of healthcare.

With a focus on scientific advancement and strategic alliances, Thermo Fisher is developing solutions that contribute significantly to the evolving landscape of pharmaceutical development. This forward-thinking approach positions it at the forefront of the industry, driving progress and improving patient outcomes.

A Deep Dive into Capabilities

Thermo Fisher, a key player in the pharmaceutical, biotechnology, and life sciences sectors, revolutionizes the journey of innovative therapies from concept to patient delivery. The company establishes itself as an indispensable partner in advancing healthcare breakthroughs by combining expertise, cutting-edge technology, and a relentless pursuit of innovation.

At the core of Thermo Fisher’s excellence lies its mastery of smallmolecule active pharmaceutical ingredients (APIs), the cornerstone of therapeutic drugs.The company’s team of experienced chemists and engineers leverages an in-depth understanding of complex chemical processes to produce APIs that meet and often exceed stringent regulatory demands. Thermo Fisher’s commitment to refining process development and scaling manufacturing processes underscores its dedication to quality and efficiency at every production phase.

Thermo Fisher’s expertise extends well beyond small molecules into solid-state chemistry, ensuring the efficacy, stability, and safety of the pharmaceuticals it develops.

“Efficacy, stability and safety are non-negotiables regarding pharmaceuticals and, therefore, to our work as a CDMO. Our customers rely on us not only to ensure their drug products meet the highest quality and regulatory standards in countries around the world but also to provide harmonized manufacturing processes that reliably develop those therapies, regardless of their molecule type or formulation,” says Jennifer Cannon, President, Commercial Operations.

For projects involving highly potent APIs (HPAPIs), Thermo Fisher employs advanced facilities and precise protocols to handle these compounds with utmost care. The company’s network includes Highly Active Substance (HAS) “mini-plants,” dedicated lab areas for potent compound processing, and specific licenses for controlled substances. These specialized capabilities set new safety and quality benchmarks in the industry.

Thermo Fisher's innovation journey reaches its peak within biologics and advanced therapies. Specializing in areas such as mammalian cell culture for therapeutic proteins, microbial fermentation, and the development of viral vectors for gene therapies, the company positions itself at the vanguard of medical innovation. Its quality commitment is further demonstrated through cGMP-compliant plasmid production, heralding new frontiers in biological therapeutics and underscoring Thermo Fisher's role in paving the way for future healthcare advancements.

The transformation of these components into patient-centric formulations showcases Thermo Fisher's dedication to enhancing drug delivery systems.

The company prioritizes improving patient outcomes by creating robust tablets, innovative capsules, reliable injectables, and targeted topical treatments. This versatility extends across numerous modalities and formulations, from sterile pre-filled syringes to liquid vials and oral solid dosage forms.

Recognizing the pivotal importance of clinical trials in the drug development continuum, Thermo Fisher offers end-to-end solutions to streamline this critical phase. Its capabilities range from producing high-caliber materials for trials to ensuring rigorous regulatory compliance facilitated by meticulous labeling and packaging. The company’s advanced analytical services are instrumental in collecting and interpreting data, empowering clients to optimize trial designs and achieve more effective outcomes.

Quality harmonization guarantees consistency, reliability and resiliency throughout the manufacturing process. Thermo Fisher champions a highly collaborative culture, ensuring that teams are well-aligned on quality objectives, oversight and a continuous improvement mindset. The company implements uniform manufacturing and technology frameworks that maintain consistent quality across its global site network, from the U.S. to Italy and Singapore.

Our Innovation Lab is a testament to our commitment to partnership. By working with our customers, we can tackle complex challenges and drive innovation that ultimately benefits patients

“The bottom line with this is assuring our partners that their drug development is safe, efficient and stable. That’s what’s most important for their patients, which means it’s also what’s most important for our teams at Thermo Fisher. We take great pride in serving the pharmaceutical value chain, and expertise in this area remains critical to do so effectively,” says Cannon.

Beyond clinical trials, Thermo Fisher adeptly bridges the transition to commercial manufacturing and distribution. Leveraging expansive production capacities and a sophisticated global supply chain, the company ensures groundbreaking treatments are delivered promptly and efficiently to patients worldwide, profoundly impacting global health access. This comprehensive approach, underpinned by a commitment to quality, efficiency, and innovation, solidifies Thermo Fisher's position as a transformative force in the pharmaceutical industry.

A Collabrative Innovation

Thermo Fisher recognizes drug development is a complex process, and tackling it with partners across the pharmaceutical and biopharmaceutical industries is essential for collective success. Its collaborative approach, therefore, is deeply embedded in its ecosystems, enabling more efficient and impactful working models that seamlessly support and accelerate the journey from molecule to market. A recent investment in this area is the opening of their Innovation Lab in Center Valley, PA. This new facility adds a physical hub for customer collaboration to Thermo Fisher's global network, allowing teams to cocreate solutions for clinical research’s most significant pain points.

“Our Innovation Lab is a testament to our commitment to partnership. By working with our customers, we can tackle complex challenges and drive innovation that ultimately benefits patients,” says Cannon.

At the Innovation Lab, Thermo Fisher's teams provide expertise and troubleshooting on key topics across the clinical supply chain, including patient data collection quality, patient non-adherence, and recruitment and retention difficulties. This initiative also underscores another essential facet of collaboration in pharma services – keeping patients and their needs at the center of all efforts.

Thermo Fisher's collaborative approach extends across its broader ecosystem, with end-to-end solutions forming a central component of its offering. Recognizing that many aspects of drug development are not one-size-fits-all, the company works closely with partners to address unique challenges at every journey step. Thermo Fisher continuously invests across a wide range of modalities and platforms—including steroids, clinical trials, viral vectors, biologics, oral solid doses, advanced therapies and commercial manufacturing—to support the latest innovations and capabilities that help drive therapies to market faster.

A Glimpse of Journey from Promise to Reality

Embarking on the transformative journey from an innovative concept to a groundbreaking medical solution, customers discover an ally in Thermo Fisher. This journey starts with a promising lead compound, riding the wave of preclinical success and facing the daunting challenge of scaling for broader applications.

At this critical juncture, the focus shifts to Thermo Fisher's Bioprocessing Collaboration Center (BCC) in St. Louis, Missouri. Equipped with cutting-edge single-use technologies, the Thermo Fisher team rises to meet and redefine the scale-up challenge, ensuring production scales both broadly and efficiently.

As the compound showcases its potential, transitioning from lab discoveries to life-saving treatments becomes the next hurdle. Thermo Fisher's advanced facilities in Lexington, MA, and across Europe play a vital role, specializing in producing viral vectors for gene therapy applications. These facilities are crucial connectors, bridging preclinical achievements and clinical trial preparedness, ensuring that the investigational product progresses seamlessly into trial phases.

Navigating the regulatory labyrinth is an intimidating part of drug development. Nevertheless, Thermo Fisher's seasoned regulatory team and its cGMP-compliant sites throughout the European heartlands, including locations in Belgium and Italy, tackle this maze with confidence. Their quality commitment and compliance ensure that the biologic meets and exceeds rigorous regulatory standards, transforming the hope of regulatory approval into a tangible milestone.

With regulatory approval, the emphasis shifts to commercial manufacturing, an essential step to satisfy the market’s growing demand. Thermo Fisher's innovative continuous manufacturing solutions are at the forefront, ensuring ample production without compromising quality. Strategic sites in Singapore and Hangzhou, China, stand ready to deliver this new hope to patients worldwide, underscoring Thermo Fisher's dedication to efficiency, sustainability, and global outreach.

Yet, even the most revolutionary treatment requires a flawless supply chain to reach its intended users. Thermo Fisher also excels in this area, providing comprehensive management and a state-of-the-art digital supply platform that boosts visibility and cooperation and ensures timely patient treatment.

In this realistic yet ideal scenario, Thermo Fisher goes beyond participating to become the catalyst that transforms a promising treatment into a global healthcare solution for autoimmune diseases. Through every development and commercialization phase, Thermo Fisher's agility, extensive capabilities, and innovative solutions lead to a successful and exemplary journey, reaffirming its commitment to advancing healthcare and enhancing lives globally.

Selecting the right CDMO partner is pivotal for the success of any drug development project. As a proud member of the expansive Thermo Fisher Scientific network, Thermo Fisher epitomizes the peak of reliability and excellence in the pharmaceutical sector. Known for its solid reputation and consistent success throughout all stages of drug development and manufacturing, Thermo Fisher stands as an essential partner.

Partnering with Thermo Fisher offers access to vast capabilities, leading-edge technologies, and the certainty of collaborating with a proven leader. On the intricate path from molecule to medicine, Thermo Fisher distinguishes itself as the definitive partner, poised to realize visionary treatments and ensure they reach those in greatest need.